Nautilus Biotechnology
Facts
- HQ
- Seattle
- Sectors
- Biotechnology Research
- Founded
- 2016
- Employees
- 150
- Stage
- Public
- Total raised
- $200M SEC Form D filings Total of this company's SEC Form D filings
- Last round
- $200M · Jun 2021 SEC Form D
- Founders
- Sujal Patel, Parag Mallick, PhD
Nautilus CEO Sujal Patel Delays Biotech Product Launch to Late 2026, Lays Off 16% Workforce Amid Strategic Shift
Nautilus Biotechnology laid off 16% of its workforce and delayed its product launch to late 2026 to pursue a higher-performance proteomics platform. CEO Sujal Patel emphasized the company’s strong financial position with over $206 million in cash despite the stock price drop.
Nautilus Biotechnology Lays Off 16% of Staff, Postpones Proteome Platform Launch to Late 2026
Nautilus Biotechnology laid off 16% of its workforce to extend its cash runway into 2027 and delayed the commercial release of its proteome analysis platform until late 2026. The company aims to control operating expenses and maximize its impact on biological science, focusing on proteomics to advance drug development.
Sujal Patel - Founder and CEO at Nautilus Biotechnology
Sujal Patel is Founder and CEO of Nautilus Biotechnology, a life sciences company creating a large-scale, single-molecule platform for quantifying and unlocking the complexity of the human proteome, with the goal of enabling fundamental advancements across human health and medicine. With nearly 20 years of executive leadership experience driving innovation for high-growth companies, Sujal is a successful entrepreneur, investor, and philanthropist who founded and served as CEO of Isilon Systems, an enterprise data storage company. After completing one of the most successful initial public offerings of 2006, Isilon was acquired by EMC in 2010 for $2.6 billion. See omnystudio.com/listener for…
People
-
Sujal Patel Executive, Co-founder and CEO, Executive Officer, Director
